Last reviewed · How we verify
Stem Cell Educator Therapy
At a glance
| Generic name | Stem Cell Educator Therapy |
|---|---|
| Also known as | Stem Cell Education |
| Sponsor | Hackensack Meridian Health |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Paresthesia
- Dizziness
- Headache
- Hypoglycemia
- Abdominal Pain
- Body Aches
- Chest Pain
- Infection Strep Throat
- Presyncope
Key clinical trials
- A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes (PHASE1)
- Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes (PHASE2, PHASE3)
- Clinical Application of Stem Cell Educator Therapy in Alopecia Areata (PHASE2)
- Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19 (PHASE2)
- Stem Cell Educator Therapy in Diabetes (PHASE2)
- Stem Cell Educator Therapy in Type 1 Diabetes (PHASE2)
- Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy (PHASE1, PHASE2)
- Mindfulness Meditation in Bone Marrow Transplantation (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stem Cell Educator Therapy CI brief — competitive landscape report
- Stem Cell Educator Therapy updates RSS · CI watch RSS
- Hackensack Meridian Health portfolio CI